Retatrutide · research summary

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

Diabetes, obesity & metabolism · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Post hoc analysis of two randomised, double-blind, placebo-controlled phase 2 trials
“Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.”

Subjects

Adults with obesity or overweight, with or without type 2 diabetes (T2D)
“In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.”

Duration

36 weeks for Study 1 and 48 weeks for Study 2
“In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.”

Reported findings

Retatrutide was associated with significant reductions in non-high-density lipoprotein cholesterol, apolipoprotein B, and triglyceride-rich lipoprotein particles in both study populations.
“In both studies, retatrutide was associated with significant reductions in non‐high‐density lipoprotein cholesterol (Study 1: up to −21.0%, Study 2: up to −26.9%), apolipoprotein B (−21.4%, −24.2%), total triglyceride‐rich lipoprotein particles (−22.5%, −33.7%), large triglyceride‐rich lipoprotein particles (−84.4%, −76.6%), triglyceride‐rich lipoprotein cholesterol (−29.4%, −38.6%), total low‐density lipoprotein particles (−19.7%, −23.5%) and small low‐density lipoprotein particles (−32.6%, −32.3%).”
Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein and interleukin-6 in the study population without T2D, but not in the population with T2D.
“Retatrutide was associated with significant reductions in high‐sensitivity C‐reactive protein (−54.8%) and interleukin‐6 (−29.6%) in Study 2 but not Study 1.”
Retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.
“In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.”

Limitations stated by the authors

Analyses were post hoc and not pre-specified, trials were less than 12 months in duration, populations were predominantly White and enrolled in the USA, and biomarkers are surrogates of cardiovascular risk.
“All analyses were performed post hoc and were not pre‐specified; although p values were adjusted for the FDR, the exploratory nature of the analyses and the number of biomarkers examined mean that the findings should be regarded as hypothesis‐generating.”

Source: PubMed 42608321 · DOI 10.1111/dom.71200 · all study summaries

Subjects

Adults with obesity or overweight, with or without type 2 diabetes (T2D)

“In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.”

Duration

36 weeks for Study 1 and 48 weeks for Study 2

“In Study 1, adults with obesity/overweight and T2D received once‐weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.”

Reported findings

Retatrutide was associated with significant reductions in non-high-density lipoprotein cholesterol, apolipoprotein B, and triglyceride-rich lipoprotein particles in both study populations.

“In both studies, retatrutide was associated with significant reductions in non‐high‐density lipoprotein cholesterol (Study 1: up to −21.0%, Study 2: up to −26.9%), apolipoprotein B (−21.4%, −24.2%), total triglyceride‐rich lipoprotein particles (−22.5%, −33.7%), large triglyceride‐rich lipoprotein particles (−84.4%, −76.6%), triglyceride‐rich lipoprotein cholesterol (−29.4%, −38.6%), total low‐density lipoprotein particles (−19.7%, −23.5%) and small low‐density lipoprotein particles (−32.6%, −32.3%).”

Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein and interleukin-6 in the study population without T2D, but not in the population with T2D.

“Retatrutide was associated with significant reductions in high‐sensitivity C‐reactive protein (−54.8%) and interleukin‐6 (−29.6%) in Study 2 but not Study 1.”

Retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.

“In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk.”

Limitations stated by the authors

Analyses were post hoc and not pre-specified, trials were less than 12 months in duration, populations were predominantly White and enrolled in the USA, and biomarkers are surrogates of cardiovascular risk.

“All analyses were performed post hoc and were not pre‐specified; although p values were adjusted for the FDR, the exploratory nature of the analyses and the number of biomarkers examined mean that the findings should be regarded as hypothesis‐generating.”